CRL

Abbott ABT reported second-quarter 2026 adjusted earnings of $1.31 per share, up 4.0% year over year. The figure beat the Zacks Consensus Estimate by 2.34%. Sales increased 13.0% year over year to $12.59 billion and surpassed the consensus mark by 0.91%. Comparable sales rose 4.8%, led by Medical Devices, while Cancer Diagnostics delivered double-digit growth. Following the earnings announcement, ABT stock rose 3.2% in pre-market trading today. Medical Devices sales increased 9.0% year over year on a reported basis to $5.85 billion. Comparable sales rose 8.4%, reflecting broad-based demand across several cardiovascular and diabetes-care businesses. Electrophysiology sales climbed 13.4% on a comparable basis, while Rhythm Management and Heart Failure advanced 9.5% and 8.7%, respectively. Diabetes Care sales grew 9.0%, supported by a 9.5% increase in continuous glucose monitor sales. Vascular sales rose 5.1%, while Structural Heart improved 5.7%. Diagnostics sales surged 42.3% on a reported basis to $3.09 billion, reflecting the March 2026 acquisition of Exact Sciences. On a comparable basis, segment sales increased 2.9%. Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote Cancer Diagnostics sales totaled $919 million and grew 13.3% on a comparable basis. Performance benefited from mid-teens Cologuard growth and contributions from precision oncology and international operations. Core Laboratory Diagnostics sales rose 3.2%, driven by strength in the United States and Latin America. Rapid and Molecular Diagnostics sales declined 8.0% on a comparable basis. The decrease reflected lower respiratory virus testing revenues compared with the prior-year period. Nutrition sales declined 3.1% year over year on a reported basis to $2.14 billion. Comparable sales fell 3.6%, reflecting lower volumes and the impact of strategic pricing actions implemented in the fourth quarter of 2025. Pediatric Nutrition sales decreased 3.1% on a comparable basis, while Adult Nutrition fell 4.0%. U.S. Nutrition remained particularly weak, with sales down 9.0%. However, total Nutrition revenues improved by $127 million sequentially from the first quarter, supported by pricing initiatives and new product launches. Established Pharmaceutical sales increased 8.4% on a reported basis to $1.50 billion. Comparable growth was 8.7%, extending the segment’s steady expa...

WILMINGTON, Mass., July 15, 2026--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 5th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260715645370/en/ Contacts Investor Relations:Todd SpencerCorporate Vice President, Investor [email protected]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Charles River Laboratories (CRL), which belongs to the Zacks Medical Services industry, could be a great candidate to consider. This medical research equipment and services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 3.84%. For the last reported quarter, Charles River came out with earnings of $2.06 per share versus the Zacks Consensus Estimate of $1.96 per share, representing a surprise of 5.10%. For the previous quarter, the company was expected to post earnings of $2.33 per share and it actually produced earnings of $2.39 per share, delivering a surprise of 2.58%. With this earnings history in mind, recent estimates have been moving higher for Charles River. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Charles River currently has an Earnings ESP of +1.43%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric. Many companies end up be...

The S&P 500 Index ($SPX) (SPY) today is down -0.15%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.23%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.30%. June E-mini S&P futures (ESM26) are down -0.17%, and June E-mini Nasdaq futures (NQM26) are up +0.24%. Stock indexes are mixed today, with the Dow Jones Industrials posting a new all-time high. Strength in chipmakers is leading the overall market higher. Stocks also garnered support on better-than-expected US economic reports on US May retail sales, a sign of resilient consumer demand, and May pending home sales. Weakness in telecommunication and trucking stocks is limiting gains in the overall market. Rocket Lab vs. Redwire: 1 Stock Has the Stronger Growth Story for the Next Decade Dear SpaceX Stock Fans, Mark Your Calendars for June 16 Dear Western Digital Stock Fans, Mark Your Calendars for June 22 Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Stocks also have carryover support from Monday after the US and Iran agreed to end their war and reopen the Strait of Hormuz, knocking crude oil prices down to a 3.5-month low and stoking risk-on sentiment in asset markets. The market’s focus will be on the conclusion of today’s 2-day FOMC meeting, the first under the leadership of new Fed Chair Kevin Warsh. While the Fed is expected to keep interest rates unchanged, the spotlight will be on how Mr. Warsh navigates the post-meeting press conference and the outlook for inflation. US MBA mortgage applications fell -3.8% in the week ended June 12, with the purchase mortgage sub-index down -3.4% and the refinancing mortgage sub-index down -4.5%. The average 30-year fixed rate mortgage was unchanged from last week at 6.60%. US May retail sales rose +0.9% m/m, stronger than expectations of +0.6% m/m. Also, May retail sales ex-autos rose +0.8% m/m, stronger than expectations of +0.6% m/m. US May pending home sales rose +3.8% m/m, stronger than expectations of +0.9% m/m and the biggest increase in 20 months. WTI crude oil prices (CLN26) recovered from a 3.5-month low today and are moving higher as prices consolidate following this week’s plunge. The eventual resumption of vessel traffic through the Strait of Hormuz could lead to the release of more than 100 laden ships ca...

Charles River Laboratories’ first quarter results reflected a mix of ongoing business transformation and operational adjustments. Management pointed to the impact of strategic divestitures, portfolio optimization, and cost-saving measures as key factors shaping performance. CEO Birgit Girshick highlighted that “incremental efficiency initiatives and divestitures” were central to margin improvement efforts, while the company also navigated discrete margin headwinds, including higher costs in its research models and services segment. The quarter was further influenced by stable demand among global pharmaceutical customers, even as small and mid-sized biotech activity varied across regions and segments. Is now the time to buy CRL? Find out in our full research report (it’s free). Revenue: $995.8 million vs analyst estimates of $977.4 million (1.2% year-on-year growth, 1.9% beat) Adjusted EPS: $2.06 vs analyst estimates of $1.94 (6% beat) Adjusted EBITDA: $214.5 million vs analyst estimates of $199.1 million (21.5% margin, 7.7% beat) Management slightly raised its full-year Adjusted EPS guidance to $11.05 at the midpoint Operating Margin: 12%, up from 7.6% in the same quarter last year Organic Revenue fell 1.5% year on year (beat) Market Capitalization: $7.84 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Elizabeth Anderson (Evercore ISI) asked about seasonal demand trends and the state of new approach methodologies (NAMs); CEO Birgit Girshick explained that seasonality is typical for the business and that NAMs will gradually expand within the core service model through both acquisitions and organic growth. Max Smock (William Blair) inquired about the year-over-year and sequential proposal volume growth; Girshick and CFO Glenn Coleman indicated high single-digit growth year-over-year for both pharma and biotech clients, with proposals rising sequentially for three straight quarters. Patrick Donnelly (Citi) focused on margin improvement timing and sustainability; Coleman detailed that margin gains in the second half will be driven by portfolio actions and cost initiatives, while Girshick noted continued sluggish...

Interested in Charles River Laboratories International, Inc.? Here are five stocks we like better. Charles River beat its prior outlook in Q1 2026, with revenue of $996 million up 1.2% year over year, though organic revenue fell 1.5% and non-GAAP EPS declined 12% to $2.06. Management said results were slightly ahead of expectations despite margin pressure from NHP costs, stock compensation tied to the CEO transition, and mix issues. The company reaffirmed full-year 2026 guidance for organic revenue down 0.5% to 1.5% and non-GAAP EPS of $10.80 to $11.30, while still expecting 120 to 150 basis points of margin expansion later in the year. Charles River also increased its reported revenue decline outlook because of a stronger U.S. dollar. Portfolio reshaping and new CEO strategy are major themes, as Birgit Girshick launched the “Pathway to Purpose” plan and the company completed or advanced several divestitures and acquisitions. Management said these moves are designed to sharpen core focus, improve profitability, and strengthen its NHP supply chain and testing capabilities. The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? Charles River Laboratories International (NYSE:CRL) reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chief Executive Officer Birgit Girshick. Girshick, who became CEO during the week of the call, said the company is entering a new phase under a strategic plan called “Pathway to Purpose,” focused on modernizing operations, strengthening its scientific portfolio, deepening client relationships and improving profitability. → Wells Fargo’s Comeback Is Real—But Not Risk-Free “The world is changing rapidly around us. Science is advancing faster than it ever has, and our clients require greater speed, best science, and more collaboration,” Girshick said. She said Charles River plans to provide more detail on the strategy at an Investor Day in September. Executive Vice President and Chief Financial Officer Glenn Coleman, who joined the company in April, said Charles River reported first-quarter revenue of $996 million, up 1.2% from a year earlier. On an organic basis, revenue declined 1.5%, which Coleman said was consistent with the company’s...

Introduced 'Pathway to Purpose,' a refreshed strategic framework focused on modernizing operations, strengthening the scientific portfolio, and enhancing client-centricity through digital tools like the Apollo platform. Performance in Q1 was impacted by discrete headwinds including higher stock compensation from the CEO transition and NHP (non-human primate) sourcing costs, though results remained in line with expectations. The DSA (Discovery and Safety Assessment) segment saw a net book-to-bill of 1.04x, signaling a solid demand environment and supporting a projected return to organic revenue growth in the second half of the year. Management attributed the RMS (Research Models and Services) revenue decline to the timing of NHP shipments and lower small model volume in North America, partially offset by robust demand in China. The company is aggressively pursuing a $100 million incremental cost savings target for 2026, part of a broader $300 million annualized efficiency initiative to drive margin expansion. Strategic acquisitions of Charles River Cambodia and PathoQuest, alongside the divestiture of CDMO and Cell Solutions, are intended to refocus the portfolio on high-margin core competencies. Management views AI as a long-term tailwind that will likely increase IND approvals by allowing biopharma clients to reinvest discovery savings into more regulated drug development programs. Reaffirmed 2026 organic revenue guidance of -0.5% to -1.5%, assuming a significant margin step-up in the second half of the year as discrete Q1 headwinds subside. Expects second-half operating margins to be over 500 basis points higher than the first half, driven primarily by the full-period impact of acquisitions and divestitures. Q2 earnings per share are projected to increase at least 30% sequentially from Q1 levels, supported by normal seasonal trends and the abatement of NHP sourcing pressures. The company anticipates approximately $0.50 to $0.55 of incremental earnings accretion in 2027 from the full-year effect of recent portfolio actions compared to 2026 levels. Guidance assumes a cautious optimism regarding biotech funding, with expectations that improved capital access for mid-sized biotechs will translate to revenue growth in late 2026. Completed the divestiture of CDMO and Cell Solutions businesses on May 6., to streamline the organizational focus on core testing serv...

Image source: The Motley Fool. Thursday, May 7, 2026 at 8:30 a.m. ET Chief Executive Officer — Birgit Girshick Chief Financial Officer — Glenn Coleman Vice President, Investor Relations — Todd Spencer Birgit Girshick, who became our Chief Executive Officer this week, and to introduce our new Executive Vice President and Chief Financial Officer, Glenn Coleman. They will comment on our results for the first quarter of 2026 as well as our financial guidance. Following the presentation, they will respond to questions. There is a slide presentation associated with today's remarks, which will be posted on the Investor Relations section of our website at ir.criver.com. A webcast replay of this call will be available beginning approximately 2 hours after the call today and can also be accessed on the Investor Relations section of our website. The replay will be available through next quarter's conference call. I'd like to remind you of our safe harbor. All remarks that we make about future expectations, plans and prospects for the company constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated. During the call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and reconciliations on our Investor Relations section of our website. I will now turn the call over to Birgit Girshick. Birgit Girshick: Thank you, Todd. It is a privilege to speak to you today as the CEO of Charles River. I would like to acknowledge Jim Foster for building this company into an industry leader and reiterate my gratitude for the mentorship that he has provided to me over the years. I step into this role with a clear understanding of Charles River today, what we can become and the tremendous responsibility we have to our clients, to the patients who rely on us, to our nearly 20,000 employees worldwide and also to you, our shareholders. I'm not taking this responsibilities lightly, and I'm energized by what lies ahead as we continue to work to help create healthier...

Charles River Laboratories International, Inc. CRL reported first-quarter 2026 adjusted earnings per share (EPS) of $2.06, down 12% year over year. The figure surpassed the Zacks Consensus Estimate by 5.1%. On a GAAP basis, the company reported a loss of 30 cents per share compared with the year-ago quarter’s earnings of 50 cents. Revenues totaled $995.8 million, which beat the Zacks Consensus Estimate by 2.5%. The top line rose 1.2% from the year-ago quarter’s level (down 1.5% organically, excluding the impact of foreign currency translation and the divestiture of a small Safety Assessment site in 2024). Following the announcement, CRL shares fell 0.7% in the pre-market trading today. The company reports under three segments — Research Models and Services (“RMS”), Discovery and Safety Assessment (“DSA”) and Manufacturing Solutions. RMS’ revenues totaled $208.4 million, down 2.2% year over year (down 5.5% organically). The organic decrease was mainly due to lower revenues for large research models and small research models in North America. Our model estimated RMS’ revenues to be $209.8 million in the first quarter. Charles River Laboratories International, Inc. price-consensus-eps-surprise-chart | Charles River Laboratories International, Inc. Quote DSA’s revenues amounted to $596.9 million, up 0.7% year over year (down 1.4% organically). The organic decline in revenues was primarily due to lower revenues for discovery services, partly from the impact of prior site consolidation activities. Our model projected revenues of $579.9 million for this segment. Manufacturing Solutions’ revenues totaled $190.5 million, up 6.8% year over year (up 2.9% organically). The organic growth was due to higher revenues in the Microbial Solutions business. Our model projected revenues to be $194.9 million for the first quarter. The gross profit in the reported quarter was $294.7 million, down 7.3% from the prior-year quarter’s level. The gross margin of 29.6% fell 269 basis points (bps) year over year. Selling, general & administrative expenses dropped 10.3% year over year to $159.4 million. The adjusted operating profit totaled $135.2 million, down 3.4% from the prior-year quarter’s level. The adjusted operating margin contracted 64 bps to 13.6%. Charles River exited the first quarter of 2026 with cash and cash equivalents of $191.8 million compared with $213.8 million at th...

Charles River Laboratories (CRL) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.96 per share. This compares to earnings of $2.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +5.24%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $2.33 per share when it actually produced earnings of $2.39, delivering a surprise of +2.58%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Charles River, which belongs to the Zacks Medical Services industry, posted revenues of $995.83 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.55%. This compares to year-ago revenues of $984.17 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Charles River shares have lost about 8.9% since the beginning of the year versus the S&P 500's gain of 7.6%. While Charles River has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Charles River was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can se...

Charles River Laboratories (CRL) reported $995.83 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 1.2%. EPS of $2.06 for the same period compares to $2.34 a year ago. The reported revenue represents a surprise of +2.55% over the Zacks Consensus Estimate of $971.06 million. With the consensus EPS estimate being $1.96, the EPS surprise was +5.24%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Charles River performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Research Models and Services: $208.37 million versus $208.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.2% change. Revenue- Manufacturing Solutions: $190.54 million compared to the $187.36 million average estimate based on three analysts. The reported number represents a change of +6.8% year over year. Revenue- Discovery and Safety Assessment: $596.92 million versus the three-analyst average estimate of $587.28 million. The reported number represents a year-over-year change of +0.7%. Operating income- Manufacturing Solutions- Non-GAAP: $49.29 million compared to the $45.39 million average estimate based on three analysts. Operating income- Discovery and Safety Assessment- Non-GAAP: $125.07 million versus $129.35 million estimated by three analysts on average. Operating income- Research Models and Services- Non-GAAP: $51.54 million versus the three-analyst average estimate of $49.93 million. Operating income- Discovery and Safety Assessment: $103.88 million compared to the $104.54 million average estimate based on two analysts. Operating income- Research Models and Services: $49.77 million compared to the $36.87 million average estimate based on two analysts. Operating income- Manufacturing Solutions: $46.84 million versus $29.7 million estimated by two...

Charles River Laboratories International (CRL) reported Q1 adjusted earnings Thursday of $2.06 per d